Humoral, cellular, clinical responses and safety of two doses of SARS-CoV-2 Messenger RNA vaccine in patients with compensated and decompensated cirrhosis: a long-term single center prospective study

Detalles Bibliográficos
Autores principales: Iavarone, M., Tosetti, G., Facchetti, F., Topa, M., Lombardi, A., D'Ambrosio, R., Degasperi, E., Loglio, A., Oggioni, C., Bandera, A., Gori, A., Ceriotti, F., Scudeller, L., Bertoletti, A., Lampertico, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
OC-1
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935161/
http://dx.doi.org/10.1016/j.dld.2022.01.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935161/
http://dx.doi.org/10.1016/j.dld.2022.01.005

Ejemplares similares